

Aplastic Anemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/A116BDD6B5AEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A116BDD6B5AEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Aplastic Anemia - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Aplastic Anemia Understanding

Aplastic Anemia: Overview

Aplastic anemia is a medical condition that damages stem cells in a person's bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time. It can be mild or severe. Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The most common cause of aplastic anemia is from your immune system attacking the stem cells in your bone marrow. Other factors that can injure bone marrow and affect blood cell production include: Radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral

infection and unknown factors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Aplastic Anemia R&D. The therapies under development are focused on novel approaches for Aplastic Anemia.

Aplastic Anemia Emerging Drugs Chapters

This segment of the Aplastic Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aplastic Anemia Emerging Drugs

PF-06462700: Pfizer

PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes. PF-06462700 is being developed by Pfizer for Aplastic anaemia and is currently in phase III stage of development.

REGN7257: Regeneron Pharmaceuticals

REGN7257 is being developed by Regeneron Pharmaceuticals for Aplastic Anemia. It is currently in phase I/II stage of development. LB-001 acts as a modulator of Interleukin 2 and immunomodular.

Further product details are provided in the report

Aplastic Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Aplastic Anemia drugs

segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aplastic Anemia

There are approx. 10+ key companies which are developing the Aplastic Anemia. The companies which have their Aplastic Anemia drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Aplastic Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aplastic Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aplastic Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aplastic Anemia drugs.

Aplastic Anemia Report Insights

Aplastic Anemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Aplastic Anemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Aplastic Anemia drugs?

How many Aplastic Anemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Aplastic Anemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aplastic Anemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Aplastic Anemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Pfizer

Regeneron Pharmaceuticals

Regen BioPharma

Omidubicel

Cellenkos

Hemogenyx

Key Products

PF-06462700

REGN7257

HemaXellerate

Gamida Cell

CK-0801

Hu PHEC

Contents

Introduction

Executive Summary

Aplastic Anemia: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Aplastic Anemia– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Aplastic Anemia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Aplastic Anemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

PF-06462700: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

Omidubicel: Gamida Cell

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Hu-PHEC: Hemogenyx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report

Inactive Products
Comparative Analysis
Aplastic Anemia Key Companies
Aplastic Anemia Key Products
Aplastic Anemia- Unmet Needs
Aplastic Anemia- Market Drivers and Barriers
Aplastic Anemia- Future Perspectives and Conclusion
Aplastic Anemia Analyst Views
Aplastic Anemia Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Aplastic Anemia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Aplastic Anemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Aplastic Anemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A116BDD6B5AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A116BDD6B5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970